Sign in
Taking people in United StatesPhase 2

Osilodrostat for mild autonomous cortisol secretion, a hormone condition

Tests the safety of 1 mg osilodrostat in adults with mild autonomous cortisol secretion.

Key facts

Who runs it
Mayo Clinic
Where
Rochester, United StatesSee the site
Trial code
Registry title
Impact of 1 mg Osilodrostat Therapy on Mild Autonomous Cortisol Secretion (MACS)
Status
Recruiting
Phase
Phase 2
People taking part
15 people, planned
Started
14 Jan 2026
Expected to end
Jan 2027
Type of study
Interventional
Treatments tested
  • Osilodrostat 1 MG
Record updated
11 February 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults with mild autonomous cortisol secretion (MACS), where the adrenal glands make slightly too much cortisol. They also need at least one related health problem.

Age
18 years or older.
Sex
All sexes can join.
Disease stage
MACS with adrenal scans showing a non-cancerous change (adrenal adenoma, or macronodular or micronodular adrenal hyperplasia). At least one of: obesity (BMI>30 kg/m2), abnormal blood sugar, abnormal blood fats, high blood pressure, osteopenia, osteoporosis or fragility fractures.
Earlier treatment
No oral glucocorticoid now or planned. No opioid use above 20 MME/day. No injected glucocorticoid in the last 6 weeks. No other planned MACS treatment.
Biomarker or test result
At least 2 abnormal dexamethasone suppression tests: 1 mg test cortisol >1.8 mcg/dL or 8 mg test cortisol >1 mcg/dL. Past results from within 24 months can count.

Main reasons for not taking part

  • Pregnancy or breastfeeding
  • Low potassium or low magnesium, or prolonged QTc on ECG
  • Uncontrolled illness such as active infection, heart failure with symptoms, unstable angina or abnormal heart rhythm
  • Known allergy to osilodrostat
  • Medicines likely to interact with the study drug

The registry criteria, word for word

Show all 23 criteriaShow less

Who can take part

  • Provide written informed consent
  • Stated willingness to comply with all study procedures and availability for the duration of the study
  • Age ≥ 18 years
  • Diagnosed with MACS; At least 2 abnormal post-dexamethasone cortisol results:; 1 mg post-dexamethasone cortisol >1.8 mcg/dL or ii. 8 mg post-dexamethasone cortisol >1 mcg/dL; Historical dexamethasone suppression test results can be used if performed within 24 months prior to enrollment
  • Adrenal imaging phenotype consistent with benign disease (adrenal adenoma/s, macronodular or micronodular adrenal hyperplasia)
  • At least one of the following comorbidities:; Obesity (BMI>30 kg/m2); Dysglycemia; Dyslipidemia; Hypertension; Osteopenia; Osteoporosis; Fragility fractures
  • Ability to take oral medication and be willing to adhere to the study intervention regimen
  • For persons of childbearing potential: agreement to remain abstinent (refrain from heterosexual intercourse) or use a contraceptive method with a failure rate of ≤ 5% per year during the treatment period and for 1 month after the last dose of study treatment

Who cannot take part

  • Planned alternative therapy for MACS during the study period
  • Current use of oral exogenous glucocorticoid therapy
  • Current use of opioid therapy >20 MME/day
  • Planned use of oral exogenous glucocorticoid therapy
  • Planned use of opioid therapy >20 MME/day
  • Concomitant therapy with medications likely to lead to drug-drug interactions (based on PI review)
  • Investigator's judgement based on history/physical examination that a comorbidity or concomitant medication may impact the hypothalamic-pituitary-adrenal axis or steroid metabolome
  • Suspected false positive post-dexamethasone cortisol results due to increased metabolism, poor absorption, or noncompliance with dexamethasone
  • Treatment with another investigational drug or other intervention within lower than specific therapy washout period
  • Uncontrolled intercurrent illness including, but not limited to:; Ongoing or active infection; Symptomatic congestive heart failure; Unstable angina pectoris; Cardiac arrhythmia; Psychiatric illness/social situations that would limit compliance with study requirements
  • Known allergic reactions to osilodrostat
  • Prolonged QTc on baseline ECG
  • Use of injectable glucocorticoid within the last 6 weeks or anticipated glucocorticoid use during the study period
  • Hypokalemia of hypomagnesemia at baseline visit
  • Pregnancy or lactation

Where in United States

  • Mayo ClinicRochester, United StatesContact: Vanessa Fell, MATaking people

About the trial

What the trial wants to find out

The purpose of this study is to evaluate the safety and tolerability of 1 mg osilodrostat therapy in patients with mild autonomous cortisol secretion (MACS), and to determine the impact on 24h urine steroid metabolome and circadian cortisol/cortisone concentrations

The group in the trial

  • Mild autonomous cortisol secretion (MACS)Treatment being tested

    Women and men diagnosed with MACS who are patients at Mayo Clinic.

    Treatment: Osilodrostat 1 MG

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.
Official title
Impact of 1 mg Osilodrostat Therapy on Mild Autonomous Cortisol Secretion (MACS)
Plain-language title
Osilodrostat for mild autonomous cortisol secretion, a hormone conditionGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 14 November 2026.
Record updated
11 February 2026